The trial will compare prodisc C Vivo and prodisc C SK with a total disc replacement device as a control to determine their safety and efficacy.
The objective of the trial will be to compare the two devices with an existing total disc replacement device that is FDA approved for two-level indications.
“Approval of the prodisc C Vivo and prodisc C SK products in the United States will enable Centinel Spine to provide the widest range of TDR products to surgeons and patients in the world,” said John Viscogliosi, chairman and CEO of Centinel Spine.
More articles on devices:
10 key updates in spinal cord injury treatment in 2019
Dr. James Harrop: The future of 3D printing and maximizing value in spine
Florida hospital 2nd to study minimally invasive spina bifida procedure
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.